Q-omics provides the consensus-scored MIR16-1 profile across patient tissues and cancer cell-line models. MIR16-1 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR16-1 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR16-1 RNA expression shows 8,032 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight CESC, STAD, and UCEC as cancer lineages where MIR16-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR16-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR16-1 survival associations across molecular data types. MIR16-1 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR16-1 RNA expression–survival associations across cancer types. High MIR16-1 expression shows unfavorable associations in CESC, SKCM, SARC, LGG, BRCA and THCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR16-1 RNA expression.
This table summarizes MIR16-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR16-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR16-1 shows higher tumor expression in STAD and ESCA. The STAD box plot shows higher MIR16-1 RNA expression in tumor versus normal tissue (log2 FC = +0.410, t-test p = .022).
This table shows molecular features associated with MIR16-1 in patient tissues and cancer cell lines. In patient samples, MIR16-1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
